On 29 May 2019, orphan designation (EU/3/19/2162) was granted by the European Commission to Pharma Gateway AB, Sweden, for emixustat hydrochloride for the treatment of Stargardt’s disease.
|Disease / condition||
Treatment of Stargardt's disease
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.